Keywords
Last Name
Institution

Senthamil Selvan

TitleAssoc Professor
InstitutionThomas Jefferson University
DepartmentMedical Oncology
Address1015 Walnut St.
Philadelphia PA 19107
Phone215-955-1195
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Masucci GV, Cesano A, Hawtin R, Janetzki S, Zhang J, Kirsch I, Dobbin KK, Alvarez J, Robbins PB, Selvan SR, Streicher HZ, Butterfield LH, Thurin M. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation. J Immunother Cancer. 2016; 4:76. PMID: 27895917.
      View in: PubMed
    2. Selvan SR, Dowling JP, Kelly WK, Lin J. Indoleamine 2,3-dioxygenase (IDO): Biology and Target in Cancer Immunotherapies. Curr Cancer Drug Targets. 2016; 16(9):755-764. PMID: 26517538.
      View in: PubMed
    3. Selvan SR, Dowling JP. "Adherent" versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer Immunotherapy. Biomed Res Int. 2015; 2015:869547. PMID: 26161419.
      View in: PubMed
    4. Kavuri V, Raghuram N, Malamud A, Selvan SR. Irritable Bowel Syndrome: Yoga as Remedial Therapy. Evid Based Complement Alternat Med. 2015; 2015:398156. PMID: 26064164.
      View in: PubMed
    5. Cao P, Selvan SR, Küpeli Akkol E, Wang N, Yang H, Cheng X. Complementary and alternative medicine in cancer prevention and therapy. Evid Based Complement Alternat Med. 2015; 2015:639372. PMID: 25922613.
      View in: PubMed
    6. Erkes DA, Selvan SR. Hapten-induced contact hypersensitivity, autoimmune reactions, and tumor regression: plausibility of mediating antitumor immunity. J Immunol Res. 2014; 2014:175265. PMID: 24949488.
      View in: PubMed
    7. Kumari J, Selvan SR, Becart S, Chattopadhyay S, Dalmo RA. Cell-mediated immunity and vaccines. J Immunol Res. 2014; 2014:632632. PMID: 24741611.
      View in: PubMed
    8. Yoshida M, Selvan S, McCue PA, Deangelis T, Baserga R, Fujii A, Rui H, Mastrangelo MJ, Sato T. Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth. Pigment Cell Melanoma Res. 2014 Mar; 27(2):297-308. PMID: 24354797.
      View in: PubMed
    9. Manjili MH, Egilmez N, Knutson KL, Selvan SR, Ostberg JR. Tumor Escape and Progression under Immune Pressure. Clin Dev Immunol. 2012; 2012:641079. PMID: 23316254.
      View in: PubMed
    10. Ben-Arye E, Cassileth B, Heusser P, Afifi F, Saad B, Selvan SR. Complementary and integrative oncology in the cross-cultural region of the middle East and South Asia. Evid Based Complement Alternat Med. 2012; 2012:940961. PMID: 22577467.
      View in: PubMed
    11. Ravindranath MH, Selvan SR, Terasaki PI. Augmentation of anti-HLA-E antibodies with concomitant HLA-Ia reactivity in IFN?-treated autologous melanoma cell vaccine recipients. J Immunotoxicol. 2012 Jul-Sep; 9(3):282-91. PMID: 22283601.
      View in: PubMed
    12. Sato T, Terai M, Tamura Y, Alexeev V, Mastrangelo MJ, Selvan SR. Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res. 2011 Dec; 51(2-3):170-82. PMID: 22139852.
      View in: PubMed
    13. Dillman RO, Fogel GB, Cornforth AN, Selvan SR, Schiltz PM, DePriest C. Features associated with survival in metastatic melanoma patients treated with patient-specific dendritic cell vaccines. Cancer Biother Radiopharm. 2011 Aug; 26(4):407-15. PMID: 21812653.
      View in: PubMed
    14. Selvan SR, Sheehy PF, Heinemann FS, Anbuganapathi S. Bone marrow failure due to T-cell large granular lymphocytic leukemia in a patient with essential thrombocythemia. Leuk Res. 2011 Feb; 35(2):278-82. PMID: 20934219.
      View in: PubMed
    15. Dillman RO, Nanci AA, Williams ST, Kim RB, Hafer RL, Coleman CL, Wang PC, Duma CM, Chen PV, Selvan SR, Cornforth AN, DePriest C. Durable complete response of refractory, progressing metastatic melanoma after treatment with a patient-specific vaccine. Cancer Biother Radiopharm. 2010 Oct; 25(5):553-7. PMID: 20849310.
      View in: PubMed
    16. Selvan SR, Carbonell DJ, Fowler AW, Beatty AR, Ravindranath MH, Dillman RO. Establishment of stable cell lines for personalized melanoma cell vaccine. Melanoma Res. 2010 Aug; 20(4):280-92. PMID: 20375743.
      View in: PubMed
    17. Dillman RO, Selvan SR, Schiltz PM, McClay EF, Barth NM, DePriest C, de Leon C, Mayorga C, Cornforth AN, Allen K. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report. Cancer Biother Radiopharm. 2009 Jun; 24(3):311-9. PMID: 19538053.
      View in: PubMed
    18. Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Thurin M, Trinchieri G, Wang E, Wigginton J, Chaussabel D, Coukos G, Dhodapkar M, Håkansson L, Janetzki S, Kleen TO, Kirkwood JM, Maccalli C, Maecker H, Maio M, Malyguine A, Masucci G, Palucka AK, Potter DM, Ribas A, Rivoltini L, Schendel D, Seliger B, Selvan S, Slingluff CL, Stroncek DF, Streicher H, Wu X, Zeskind B, Zhao Y, Zocca MB, Zwierzina H, Marincola FM. A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med. 2008; 6:81. PMID: 19105846.
      View in: PubMed
    19. Selvan SR, Dillman RO, Fowler AW, Carbonell DJ, Ravindranath MH. Monitoring response to treatment in melanoma patients: potential of a serum glycomic marker. Int J Cancer. 2008 Mar 15; 122(6):1374-83. PMID: 17960619.
      View in: PubMed
    20. Kumar M, Samarth R, Kumar M, Selvan SR, Saharan B, Kumar A. Protective effect of Adhatoda vascia Nees against radiation-induced damage at cellular, biochemical and chromosomal levels in Swiss albino mice. Evid Based Complement Alternat Med. 2007 Sep; 4(3):343-50. PMID: 17965765.
      View in: PubMed
    21. Ravindranath MH, Muthugounder S, Presser N, Selvan SR, Santin AD, Bellone S, Saravanan TS, Morton DL. Immunogenic gangliosides in human ovarian carcinoma. Biochem Biophys Res Commun. 2007 Feb 9; 353(2):251-8. PMID: 17188646.
      View in: PubMed
    22. Dillman RO, Selvan SR, Schiltz PM. Patient-specific dendritic-cell vaccines for metastatic melanoma. N Engl J Med. 2006 Sep 14; 355(11):1179-81. PMID: 16971731.
      View in: PubMed
    23. Ravindranath MH, Saravanan TS, Monteclaro CC, Presser N, Ye X, Selvan SR, Brosman S. Epicatechins Purified from Green Tea (Camellia sinensis) Differentially Suppress Growth of Gender-Dependent Human Cancer Cell Lines. Evid Based Complement Alternat Med. 2006 Jun; 3(2):237-47. PMID: 16786054.
      View in: PubMed
    24. Dillman RO, Beutel L, Nayak S, Depriest C, Selvan S, Schiltz P. Cancer vaccine potency: is there a dose/response relationship for patient-specific vaccines and clinical outcomes? Cancer Biother Radiopharm. 2005 Aug; 20(4):373-8. PMID: 16114985.
      View in: PubMed
    25. Selvan SR, Cornforth AN, Rao NP, Reid YA, Schiltz PM, Liao RP, Price DT, Heinemann FS, Dillman RO. Establishment and characterization of a human primary prostate carcinoma cell line, HH870. Prostate. 2005 Apr 1; 63(1):91-103. PMID: 15468172.
      View in: PubMed
    26. Ravindranath MH, Muthugounder S, Presser N, Selvan SR, Portoukalian J, Brosman S, Morton DL. Gangliosides of organ-confined versus metastatic androgen-receptor-negative prostate cancer. Biochem Biophys Res Commun. 2004 Nov 5; 324(1):154-65. PMID: 15464996.
      View in: PubMed
    27. Dillman R, Barth N, Selvan S, Beutel L, de Leon C, DePriest C, Peterson C, Nayak S. Phase I/II trial of autologous tumor cell line-derived vaccines for recurrent or metastatic sarcomas. Cancer Biother Radiopharm. 2004 Oct; 19(5):581-8. PMID: 15650450.
      View in: PubMed
    28. Dillman R, Selvan S, Schiltz P, Peterson C, Allen K, Depriest C, McClay E, Barth N, Sheehy P, de Leon C, Beutel L. Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis. Cancer Biother Radiopharm. 2004 Oct; 19(5):658-65. PMID: 15650459.
      View in: PubMed
    Selvan's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _